NeoImmuneTech Balance Sheet Health
Financial Health criteria checks 6/6
NeoImmuneTech has a total shareholder equity of ₩74.9B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩90.5B and ₩15.7B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
Interest coverage ratio | n/a |
Cash | ₩69.07b |
Equity | ₩74.86b |
Total liabilities | ₩15.66b |
Total assets | ₩90.51b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A950220's short term assets (₩72.3B) exceed its short term liabilities (₩12.9B).
Long Term Liabilities: A950220's short term assets (₩72.3B) exceed its long term liabilities (₩2.8B).
Debt to Equity History and Analysis
Debt Level: A950220 is debt free.
Reducing Debt: A950220 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A950220 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A950220 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 19.7% each year.